Edition:
India

Ose Immunotherapeutics SA (OSE.PA)

OSE.PA on Paris Stock Exchange

3.80EUR
19 Jul 2019
Change (% chg)

€0.15 (+4.11%)
Prev Close
€3.65
Open
€3.65
Day's High
€3.82
Day's Low
€3.64
Volume
8,891
Avg. Vol
7,477
52-wk High
€4.44
52-wk Low
€2.70

Latest Key Developments (Source: Significant Developments)

Ose Immunotherapeutics Continuation Of “Atalante 1” Phase 3 Clinical Trial Of Tedopi
Thursday, 20 Jun 2019 

June 20 (Reuters) - Ose Immunotherapeutics SA ::OSE IMMUNOTHERAPEUTICS: CONTINUATION OF “ATALANTE 1” PHASE 3 CLINICAL TRIAL OF TEDOPI® IN NSCLC PATIENTS POST CHECKPOINT INHIBITOR FAILURE FOLLOWING IDMC RECOMMENDATION.IDMC SAW NO SAFETY CONCERNS AND RECOMMENDED CONTINUATION OF PATIENT RECRUITMENT, WITHOUT ANY MODIFICATIONS, OF ITS ONGOING INTERNATIONAL PIVOTAL PHASE 3 TRIAL, CALLED ATALANTE 1, EVALUATING TEDOPI IN HLA-A2 POSITIVE NON-SMALL CELL LUNG CANCER (NSCLC) PATIENTS POST IMMUNE CHECKPOINT INHIBITOR FAILURE (PD-1/PD-L1).  Full Article

OSE Immunotherapeutics: Issuance Of Canadian Patent, Notice Of Allowance Of US Patent
Tuesday, 9 Apr 2019 

April 9 (Reuters) - OSE IMMUNOTHERAPEUTICS SA ::OSE IMMUNOTHERAPEUTICS ANNOUNCES ISSUANCE OF CANADIAN PATENT AND NOTICE OF ALLOWANCE OF U.S. PATENT PROTECTING CD28-ANTAGONIST IMMUNOTHERAPY FR104.COVER THERAPEUTIC APPLICATIONS OF FR104 THROUGH 2031.IN CANADA AND IN THE U.S. IN AUTOIMMUNE DISEASES, CHRONIC INFLAMMATORY DISEASES AND GRAFT APPLICATIONS .  Full Article

Ose Immunotherapeutics FY Total Revenues Up At 24.5 Million Euros
Thursday, 28 Mar 2019 

March 28 (Reuters) - OSE IMMUNOTHERAPEUTICS SA ::FY NET INCOME EUR 5.5‍​ MILLION VERSUS LOSS OF EUR 10.5 MILLION YEAR AGO.FY OPERATING INCOME EUR 4.8‍​ MILLION VERSUS LOSS OF EUR 12.6 MILLION YEAR AGO.2018 YEAR-END CASH POSITION OF EUR 12.4 MILLION.ADDITIONAL MILESTONE PAYMENTS FROM SERVIER AND BOEHRINGER INGELHEIM RECEIVED IN 2019 PROVIDE FUNDING UNTIL END OF 2020.APPOINTS DOMINIQUE COSTANTINI AS CHAIRMAN OF THE BOARD OF DIRECTORS.FY TOTAL REVENUES EUR 24.5 MILLION VERSUS EUR 6.7 MILLION YEAR AGO.APPOINTS ALEXIS PEYROLES AS CHIEF EXECUTIVE OFFICER.  Full Article

Ose Immunotherapeutics: New Research Collaboration With Léon Bérard Cancer Center
Tuesday, 26 Mar 2019 

March 26 (Reuters) - OSE IMMUNOTHERAPEUTICS SA ::OSE IMMUNOTHERAPEUTICS ANNOUNCES NEW RESEARCH COLLABORATION WITH LÉON BÉRARD CANCER CENTER TO USE ARTIFICIAL INTELLIGENCE TECHNOLOGIES TO IDENTIFY NOVEL IMMUNO-ONCOLOGY TARGETS.  Full Article

OSE Immunotherapeutics Receives Belgian Authorization For Phase 1 Clinical Trial To Evaluate Anti-IL-7 Receptor Antagonist OSE-127
Monday, 26 Nov 2018 

Nov 26 (Reuters) - OSE IMMUNOTHERAPEUTICS SA ::OSE IMMUNOTHERAPEUTICS RECEIVES BELGIAN AUTHORIZATION FOR A PHASE 1 CLINICAL TRIAL TO EVALUATE ANTI-IL-7 RECEPTOR ANTAGONIST OSE-127.A TOTAL OF 63 HEALTHY VOLUNTEERS WILL BE ENROLLED IN THIS RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY..OSE-127 IS BEING DEVELOPED UNDER AN OPTION LICENSE AGREEMENT WITH SERVIER.  Full Article

Ose Immunotherapeutics Submits Application To Evaluate Tedopi
Wednesday, 10 Oct 2018 

Oct 10 (Reuters) - OSE IMMUNOTHERAPEUTICS SA ::OSE IMMUNOTHERAPEUTICS AND ONCOLOGY PHYSICIAN NETWORK GERCOR ANNOUNCE SUBMISSION OF INVESTIGATIONAL NEW DRUG APPLICATION TO EVALUATE TEDOPI® IN COMBINATION WITH NIVOLUMAB IN PANCREATIC CANCER.TRIAL WILL COMPARE TEDOPI, 10 NEOEPITOPES ASSOCIATED TO ACTIVATE CYTOTOXIC T-LYMPHOCYTES, IN COMBINATION WITH NIVOLUMAB.  Full Article

Ose Immunotherapeutics Announces Submission Of Investigational New Drug Application To Evaluate Tedopi® Combined With Nivolumab In Pancreatic Cancer
Wednesday, 10 Oct 2018 

Oct 10 (Reuters) - OSE IMMUNOTHERAPEUTICS SA ::OSE IMMUNOTHERAPEUTICS AND ONCOLOGY PHYSICIAN NETWORK GERCOR ANNOUNCE SUBMISSION OF INVESTIGATIONAL NEW DRUG APPLICATION TO EVALUATE TEDOPI® IN COMBINATION WITH NIVOLUMAB IN PANCREATIC CANCER.PHASE 2 CLINICAL TRIAL OF TEDOPI® IN PANCREATIC CANCER WILL BE SPONSORED BY ONCOLOGY GROUP GERCOR.STUDY WILL EXPLORE TEDOPI®'S POTENTIAL IN AN ADDITIONAL ONCOLOGY INDICATION.COMPANY EXPECTS ACTIVATION OF TRIAL AND OPENING OF CLINICAL CENTERS IN EARLY 2019.  Full Article

OSE Immunotherapeutics Announces Issuance Of European Patent Protecting FR104, CD28-Antagonist Immunotherapy
Tuesday, 11 Sep 2018 

Sept 11 (Reuters) - OSE IMMUNOTHERAPEUTICS SA ::OSE IMMUNOTHERAPEUTICS ANNOUNCES ISSUANCE OF A EUROPEAN PATENT PROTECTING FR104, CD28-ANTAGONIST IMMUNOTHERAPY.PATENT COVERS THERAPEUTIC APPLICATIONS OF FR104 IN EUROPE IN AUTOIMMUNE DISEASES, CHRONIC INFLAMMATORY DISEASES AND GRAFT APPLICATIONS THROUGH 2031.  Full Article

Ose Immunotherapeutics H1 Operating Result Turns To Profit Of 10.2 Million Euros
Thursday, 6 Sep 2018 

Sept 6 (Reuters) - OSE IMMUNOTHERAPEUTICS SA ::OSE IMMUNOTHERAPEUTICS REPORTS FIRST-HALF 2018 RESULTS AND PROVIDES A CORPORATE UPDATE.AVAILABLE CASH AS OF JUNE 30, 2018 OF EUR 18.6 M.SAYS H1 NET PROFIT OF €8.9 MILLION DUE TO THE PARTNERSHIP SIGNED WITH BOEHRINGER INGELHEIM.H1 OPERATING PROFIT EUR 10.2 MILLION VERSUS LOSS OF EUR 7.3 MILLION YEAR AGO.PROGRESSED PHASE 3 CLINICAL TRIAL OF TEDOPI® IN PATIENTS WITH NSCLC WHO FAILED TREATMENT WITH PD-1/PD-L1 IMMUNE CHECKPOINT INHIBITORS.  Full Article

Ose Immunotherapeutics FY Revenue Up At 6.7 Million Euros
Wednesday, 28 Mar 2018 

March 28 (Reuters) - OSE IMMUNOTHERAPEUTICS SA ::TEDOPI: REDEPLOYMENT OF THE PHASE 3 CLINICAL PHASE IN EARLY 2018.TEDOPI: PHASE 2 TRIAL IN PANCREATIC CANCER INITIATION IS EXPECTED IN 2018.OSE-172: ENTRY INTO CLINICAL PHASE PLANNED IN 2018.FY OPERATING LOSS EUR 12.6 MILLION VERSUS PROFIT EUR 17.5 MILLION YEAR AGO.FY NET LOSS EUR 10.5 MILLION VERSUS PROFIT EUR 20.7 MILLION YEAR AGO.CASH AVAILABLE AS OF DECEMBER 31, 2017 OF EUR 12.5 MILLION VERSUS EUR 17.8 MILLION YEAR AGO.FY REVENUE EUR 6.7 MILLION VERSUS EUR 383,000 YEAR AGO.  Full Article